Cargando…
Treatment of solid tumors with immunotoxins
Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin ar...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242142/ https://www.ncbi.nlm.nih.gov/pubmed/16168135 http://dx.doi.org/10.1186/bcr1284 |
_version_ | 1782125603752771584 |
---|---|
author | Messmer, Davorka Kipps, Thomas J |
author_facet | Messmer, Davorka Kipps, Thomas J |
author_sort | Messmer, Davorka |
collection | PubMed |
description | Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin are but a few of the factors that govern the effectiveness of these compounds in the treatment of patients with cancer. Improvements in design, synthesis, and delivery of these molecules may permit them to become significant components in the arsenal of targeted therapies for cancer. |
format | Text |
id | pubmed-1242142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-12421422005-10-06 Treatment of solid tumors with immunotoxins Messmer, Davorka Kipps, Thomas J Breast Cancer Res Commentary Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin are but a few of the factors that govern the effectiveness of these compounds in the treatment of patients with cancer. Improvements in design, synthesis, and delivery of these molecules may permit them to become significant components in the arsenal of targeted therapies for cancer. BioMed Central 2005 2005-07-12 /pmc/articles/PMC1242142/ /pubmed/16168135 http://dx.doi.org/10.1186/bcr1284 Text en Copyright © 2005 BioMed Central Ltd |
spellingShingle | Commentary Messmer, Davorka Kipps, Thomas J Treatment of solid tumors with immunotoxins |
title | Treatment of solid tumors with immunotoxins |
title_full | Treatment of solid tumors with immunotoxins |
title_fullStr | Treatment of solid tumors with immunotoxins |
title_full_unstemmed | Treatment of solid tumors with immunotoxins |
title_short | Treatment of solid tumors with immunotoxins |
title_sort | treatment of solid tumors with immunotoxins |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242142/ https://www.ncbi.nlm.nih.gov/pubmed/16168135 http://dx.doi.org/10.1186/bcr1284 |
work_keys_str_mv | AT messmerdavorka treatmentofsolidtumorswithimmunotoxins AT kippsthomasj treatmentofsolidtumorswithimmunotoxins |